Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

More to come: humoral immune responses in MS.
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (MIRROR)
Accentia Biopharmaceuticals Conducts Investigator Meeting in Preparation for New Multiple Sclerosis Drug Study for Cyrevia™
A urinary test procedure for identification of cannabidiol in patients undergoing medical therapy with marijuana.
Fatal Acute Myeloid Leukemia With 11q23 MLL Gene Rearrangement Following Mitoxantrone Treatment in a Case of Childhood-onset Multiple Sclerosis.
UCSF Neuroimmunology Seminar
Receptos announces issuance of composition of matter patents covering proprietary lead product candidate RPC1063
Toxicity of Teriflunomide in Aryl Hydrocarbon Receptor Deficient Mice.
Daclizumab Therapy for Multiple Sclerosis.
First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models.
Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.
Testing for urinary tract colonisation before high-dose corticosteroid treatment in acute multiple sclerosis relapses: prospective algorithm validation.
A novel pH-sensitive interferon-β (INF-β) oral delivery system for application in multiple sclerosis.
Sample-size calculations for short-term proof-of-concept studies of tissue protection and repair in multiple sclerosis lesions via conventional clinical imaging
The correlation between symptomatic fatigue to definite measures of gait in people with multiple sclerosis.
BTG plc Close Period Update
Efficacy and Tolerability of BAF312 in Patients With Polymyositis
Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis (ITT-PMS)
Th17 cells: A prognostic marker for MS rebound after natalizumab cessation?
Arzerra
BG00012 and Disability Progression in Secondary Progressive Multiple Sclerosis (SPMS) (INSPIRE)
IgE-Mediated Allergic Reactions after the First Administration of Glatiramer Acetate in Patients with Multiple Sclerosis.
Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.
Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder.
Impact of sleep disorder treatment on fatigue in multiple sclerosis.

Pages